FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119027045> ?p ?o ?g. }

• W2119027045 endingPage "41" @default.
• W2119027045 startingPage "41" @default.
• W2119027045 abstract "Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes Richard D O&#39;ConnorSharp Rees-Stealy Medical Group, San Diego, CA, USAAbstract: In the United States, budesonide/formoterol pressurized metered-dose inhaler (pMDI) is approved for treatment of asthma in patients aged ≥12 years whose asthma is not adequately controlled with an inhaled corticosteroid (ICS) or whose disease severity clearly warrants treatment with an ICS and a long-acting β2-adrenergic agonist. This article reviews studies of budesonide/formoterol pMDI in patients with persistent asthma, with a particular focus on patient-reported outcomes (eg, perceived onset of effect, patient satisfaction with treatment, health-related quality of life [HRQL], global assessments, sleep quality and quantity), as these measures reflect patient perceptions of asthma control and disease burden. A search of PubMed and respiratory meetings was performed to identify relevant studies. In two pivotal budesonide/formoterol pMDI studies in adolescents and adults, greater efficacy and similar tolerability were shown with budesonide/formoterol pMDI 160/9 µg and 320/9 µg twice daily versus its monocomponents or placebo. In those studies, improvements in HRQL, patient satisfaction, global assessments of asthma control, and quality of sleep also favored budesonide/formoterol pMDI compared with one or both of its monocomponents or placebo. Budesonide/formoterol pMDI has a rapid onset of effect (within 15 minutes) that patients can feel, an attribute that may have benefits for treatment adherence. In summary, budesonide/formoterol pMDI is effective and well tolerated and has additional therapeutic benefits that may be important from the patient’s perspective.Keywords: budesonide, formoterol, patient-reported outcomes, efficacy, tolerability, onset of effect" @default.
• W2119027045 created "2016-06-24" @default.
• W2119027045 creator A5090213930 @default.
• W2119027045 date "2011-01-01" @default.
• W2119027045 modified "2023-09-28" @default.
• W2119027045 title "Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes" @default.
• W2119027045 cites W128731631 @default.
• W2119027045 cites W1924413082 @default.
• W2119027045 cites W1972693426 @default.
• W2119027045 cites W1972813104 @default.
• W2119027045 cites W1976421392 @default.
• W2119027045 cites W1985655856 @default.
• W2119027045 cites W1988431729 @default.
• W2119027045 cites W1991112399 @default.
• W2119027045 cites W1991119065 @default.
• W2119027045 cites W1997314662 @default.
• W2119027045 cites W2000694274 @default.
• W2119027045 cites W2005607395 @default.
• W2119027045 cites W2013599050 @default.
• W2119027045 cites W2014186397 @default.
• W2119027045 cites W2015669549 @default.
• W2119027045 cites W2018925087 @default.
• W2119027045 cites W2019665207 @default.
• W2119027045 cites W2020123515 @default.
• W2119027045 cites W2024265404 @default.
• W2119027045 cites W2024304340 @default.
• W2119027045 cites W2024585538 @default.
• W2119027045 cites W2035250137 @default.
• W2119027045 cites W2038722323 @default.
• W2119027045 cites W2039246964 @default.
• W2119027045 cites W2041256289 @default.
• W2119027045 cites W2041998278 @default.
• W2119027045 cites W2044596561 @default.
• W2119027045 cites W2045002632 @default.
• W2119027045 cites W2046293056 @default.
• W2119027045 cites W2047439496 @default.
• W2119027045 cites W2050477739 @default.
• W2119027045 cites W2055236553 @default.
• W2119027045 cites W2056770521 @default.
• W2119027045 cites W2061683646 @default.
• W2119027045 cites W2082690625 @default.
• W2119027045 cites W2086167722 @default.
• W2119027045 cites W2086416159 @default.
• W2119027045 cites W2087666617 @default.
• W2119027045 cites W2087760311 @default.
• W2119027045 cites W2091150911 @default.
• W2119027045 cites W2096043817 @default.
• W2119027045 cites W2097762785 @default.
• W2119027045 cites W2105007000 @default.
• W2119027045 cites W2105665234 @default.
• W2119027045 cites W2112074549 @default.
• W2119027045 cites W2113552278 @default.
• W2119027045 cites W2124670436 @default.
• W2119027045 cites W2145513806 @default.
• W2119027045 cites W2152599196 @default.
• W2119027045 cites W2153236387 @default.
• W2119027045 cites W2155017568 @default.
• W2119027045 cites W2160621537 @default.
• W2119027045 cites W2169433957 @default.
• W2119027045 cites W228126680 @default.
• W2119027045 cites W2601675613 @default.
• W2119027045 cites W81525192 @default.
• W2119027045 cites W2168501375 @default.
• W2119027045 doi "https://doi.org/10.2147/prom.s16159" @default.
• W2119027045 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3417922" @default.
• W2119027045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22915968" @default.
• W2119027045 hasPublicationYear "2011" @default.
• W2119027045 type Work @default.
• W2119027045 sameAs 2119027045 @default.
• W2119027045 citedByCount "1" @default.
• W2119027045 countsByYear W21190270452018 @default.
• W2119027045 crossrefType "journal-article" @default.
• W2119027045 hasAuthorship W2119027045A5090213930 @default.
• W2119027045 hasBestOaLocation W21190270451 @default.
• W2119027045 hasConcept C126322002 @default.
• W2119027045 hasConcept C142724271 @default.
• W2119027045 hasConcept C177713679 @default.
• W2119027045 hasConcept C1862650 @default.
• W2119027045 hasConcept C197934379 @default.
• W2119027045 hasConcept C204787440 @default.
• W2119027045 hasConcept C27081682 @default.
• W2119027045 hasConcept C2776042228 @default.
• W2119027045 hasConcept C2776136866 @default.
• W2119027045 hasConcept C2777450039 @default.
• W2119027045 hasConcept C2778375690 @default.
• W2119027045 hasConcept C2779871671 @default.
• W2119027045 hasConcept C2780261241 @default.
• W2119027045 hasConcept C2780667556 @default.
• W2119027045 hasConcept C2909086917 @default.
• W2119027045 hasConcept C42219234 @default.
• W2119027045 hasConcept C71924100 @default.
• W2119027045 hasConceptScore W2119027045C126322002 @default.
• W2119027045 hasConceptScore W2119027045C142724271 @default.
• W2119027045 hasConceptScore W2119027045C177713679 @default.
• W2119027045 hasConceptScore W2119027045C1862650 @default.
• W2119027045 hasConceptScore W2119027045C197934379 @default.
• W2119027045 hasConceptScore W2119027045C204787440 @default.
• W2119027045 hasConceptScore W2119027045C27081682 @default.

• next